Cullinan Therapeutics (CGEM) Projected to Announce Earnings on Thursday

by · The Markets Daily

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.8435) per share and revenue of $2.00 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, analysts expect Cullinan Therapeutics to post ($3.06) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

Cullinan Therapeutics stock traded up $0.88 during mid-day trading on Tuesday, reaching $15.81. 35,680 shares of the company were exchanged, compared to its average volume of 886,723. The firm has a market cap of $1.02 billion, a P/E ratio of -5.06 and a beta of -0.05. Cullinan Therapeutics has a 12-month low of $6.73 and a 12-month high of $23.19. The business has a fifty day moving average of $17.77 and a 200 day moving average of $15.79.

Analyst Upgrades and Downgrades

CGEM has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 24th. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Cullinan Therapeutics in a research note on Friday, October 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Friday, October 2nd. Wedbush upped their price objective on Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. Finally, BTIG Research lifted their price target on Cullinan Therapeutics from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.86.

View Our Latest Research Report on CGEM

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total value of $172,560.00. Following the completion of the sale, the insider directly owned 158,844 shares of the company’s stock, valued at approximately $3,426,265.08. This represents a 4.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 8.60% of the company’s stock.

Cullinan Therapeutics Company Profile

(Get Free Report)

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors.

Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers.

Further Reading